Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Alma, Michigan 48801


Acute Mountain Sickness (AMS) is a well-documented syndrome that affects 42% of non-acclimatized individuals traveling to altitudes above 10,000 feet. Decreased barometric pressure, which leads to low blood oxygen levels, is the primary casual factor of AMS. Symptoms of AMS are characterized by headache, nausea, vomiting, dizziness, fatigue and difficultly sleeping. Moreover, when people travel to high altitude, cognitive performance and endurance exercise capacity are impaired. Therefore, the goal of this research is to identify effective pharmacological agents that will help reduce the symptoms of AMS and improve physical and cognitive performance at high altitude. The investigators will study the efficacy of the dietary supplement, quercetin, the drugs nifedipine (extended release) and methazolamide taken together, the drug metformin, and the drug nitrite in reducing symptoms of AMS and improving cognitive and exercise performance at high altitudes.


Inclusion Criteria: - healthy, - young (18-30 years old) men who can meet APFT requirements for special operation forces (SOF) training as outlined by the US Army (42 push ups, 53 sit-ups, 6 pull-ups, 2 mile run in < 15 min 54 s) Exclusion Criteria: - women; - smokers; - participants with diseases or disorders known to be affected by hypoxia or the drugs used in this study, such as hypotension, anemia, sickle cell trait or disease, and diabetes; - participants with a history of significant head injury, migraines or seizures; - participants taking any medication (over-the-counter or prescription) or herbal supplements; - participants with known flavonoid allergies; - participants with known allergies to metformin; - participants with known hypersensitivity reaction to nifedipine; - participants with known allergies to sulfonamide-based drugs; - participants with inability to be headache-free when consuming the amount of caffeine in two six ounce cups of coffee or less per day; - exposure to high altitude above 1000m in the previous three months; or - participants who have been on an airline flight over six hours (the lowered cabin pressure for an extended period of time approximates exposure to high altitude); - participants who are unable to achieve the minimum physical criteria required for SOF training



Primary Contact:

Principal Investigator
Robert Roach, PhD
University of Colorado Anschutz Medical Campus, Altitude Research Center

Backup Contact:


Location Contact:

Alma, Michigan 48801
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.